Physician profile
Jesse Karpman
NPI 1801997515
$5,613.93
in general payments reported to CMS, 2019-2025
25 companies · $1,154 in 2025
The $1,154 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $574 · 2020: $612 · 2021: $700 · 2022: $802 · 2023: $912 · 2024: $860 · 2025: $1,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,926.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,925.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,278.11 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,114.45 | 2020-2025 | Breztri, Tezspire, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $437.81 | 2021-2025 | |
| Mylan Specialty L.P. | $221.65 | 2019-2024 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $215.58 | 2019-2025 | Opsumit, Opsynvi, Uptravi |
| Genzyme Corporation | $204.11 | 2020-2024 | |
| Viatris Specialty LLC | $177.58 | 2025 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.34 | 2019-2023 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Regeneron Healthcare Solutions, INC. | $139.21 | 2019-2025 | Dupixent |
| Sunovion Pharmaceuticals INC. | $108.08 | 2019-2020 | |
| Pfizer INC. | $101.10 | 2019-2021 | |
| United Therapeutics Corporation | $77.88 | 2024-2025 | Tyvaso, Tyvaso |
| Philips North America LLC | $61.69 | 2019-2021 | |
| Amgen INC. | $46.15 | 2025 | Tezspire |
| Insmed, INC. | $43.15 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| 3b Medical, INC. | $38.72 | 2025 | Luna |
| Advanced Respiratory, INC | $37.53 | 2019-2020 | |
| Inspire Medical Systems, INC. | $24.88 | 2024 | Inspire |
| Grifols USA, LLC | $23.74 | 2021 | |
| Lilly USA, LLC | $17.64 | 2025 | Zepbound |
| Mallinckrodt Hospital Products INC. | $16.38 | 2024 | Acthar |
| Takeda Pharmaceuticals U.S.A., INC. | $14.80 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.25 | 2021 | |
| Gilead Sciences, INC. | $13.23 | 2019 | |
| Genentech USA, INC. | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Karpman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.